Tomeh Mhd Anas, Hadianamrei Roja, Sun Weizhen, Xu Defeng, Brown Stephen, Zhao Xiubo
Department of Chemical and Biological Engineering, University of Sheffield, Sheffield S1 3JD, UK.
School of Pharmacy, Changzhou University, Changzhou 213164, China.
J Colloid Interface Sci. 2021 Jul 15;594:513-521. doi: 10.1016/j.jcis.2021.03.086. Epub 2021 Mar 18.
One of the main challenges in cancer therapy is the poor water solubility of many anticancer drugs which results in low bioavailability at the tumour sites and reduced efficacy. The currently available polymer-based anticancer drug delivery systems often suffer from low encapsulation efficiency, uncontrolled release, and lack of long-term stability. Herein, we report the development of novel stiffness-tuneable core-shell nanocarriers composed of naturally derived polymers silk fibroin (SF) and sodium alginate (SA) inside a liposomal shell for enhanced cellular uptake and controlled release of hydrophobic anticancer agent ASC-J9 (Dimethylcurcumin). It is anticipated that the stiffness of the nanocarriers has a significant effect on their cellular uptake and anticancer efficacy.
The nanocarriers were prepared by thin film hydration method followed by extrusion and cross-linking of SA to obtain a uniform size and shape, avoiding harsh processing conditions. The structural transformation of SF in the nanocarriers induced by SA crosslinking was determined using Fourier transform infrared (FTIR) spectroscopy. The size, zeta potential, morphology and stiffness of the nanocarriers were measured using dynamic light scattering (DLS), transmission electron microscopy (TEM) and atomic force microscopy (AFM). Drug loading and release were measured using UV-Vis spectrophotometry. The cellular uptake and anticancer efficacy of the nanocarriers were studied in HCT 116 human colorectal adenocarcinoma cells and 3D tumour spheroids using high content microscopy.
The synthesized nanocarriers had high encapsulation efficiency (62-78%) and were physically stable for up to 5 months at 4 ˚C. The release profile of the drug from the nanocarriers was directed by their stiffness and was easily tuneable by changing the ratio of SF to SA in the core. Furthermore, the designed nanocarriers improved the cellular uptake and anticancer activity of ASC-J9, and enhanced its tumour penetration in HCT 116 3D colorectal cancer spheroids. These findings suggest that the designed core-shell nanocarriers can be used as a highly efficient drug delivery system for cancer therapy.
癌症治疗的主要挑战之一是许多抗癌药物的水溶性差,这导致肿瘤部位的生物利用度低,疗效降低。目前可用的基于聚合物的抗癌药物递送系统常常存在包封效率低、释放不受控制以及缺乏长期稳定性的问题。在此,我们报告了一种新型的刚度可调核壳纳米载体的开发,该纳米载体由天然衍生的聚合物丝素蛋白(SF)和海藻酸钠(SA)组成,包裹在脂质体壳内,用于增强细胞摄取和控制疏水性抗癌剂ASC-J9(二甲基姜黄素)的释放。预计纳米载体的刚度对其细胞摄取和抗癌疗效有显著影响。
通过薄膜水化法制备纳米载体,随后对SA进行挤压和交联,以获得均匀的尺寸和形状,避免苛刻的加工条件。使用傅里叶变换红外(FTIR)光谱法测定SA交联诱导的纳米载体中SF的结构转变。使用动态光散射(DLS)、透射电子显微镜(TEM)和原子力显微镜(AFM)测量纳米载体的尺寸、zeta电位、形态和刚度。使用紫外可见分光光度法测量药物负载和释放。使用高内涵显微镜在HCT 116人结肠腺癌细胞和3D肿瘤球体中研究纳米载体的细胞摄取和抗癌疗效。
合成的纳米载体具有高包封效率(62-78%),并且在4℃下长达5个月物理稳定。药物从纳米载体的释放曲线由其刚度决定,并且通过改变核中SF与SA的比例可以很容易地调节。此外,设计的纳米载体提高了ASC-J9的细胞摄取和抗癌活性,并增强了其在HCT 116 3D结肠直肠癌球体中的肿瘤穿透性。这些发现表明,设计的核壳纳米载体可作为一种高效的癌症治疗药物递送系统。